ATE470439T1 - Verwendung von hif 1alfa modulatoren zur behandlung von krebs - Google Patents

Verwendung von hif 1alfa modulatoren zur behandlung von krebs

Info

Publication number
ATE470439T1
ATE470439T1 AT06784964T AT06784964T ATE470439T1 AT E470439 T1 ATE470439 T1 AT E470439T1 AT 06784964 T AT06784964 T AT 06784964T AT 06784964 T AT06784964 T AT 06784964T AT E470439 T1 ATE470439 T1 AT E470439T1
Authority
AT
Austria
Prior art keywords
1alfa
hif
modulators
treat cancer
treating
Prior art date
Application number
AT06784964T
Other languages
English (en)
Inventor
Todd Seeley
David Liu
Stephen Klauss
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE470439T1 publication Critical patent/ATE470439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06784964T 2005-06-15 2006-06-15 Verwendung von hif 1alfa modulatoren zur behandlung von krebs ATE470439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69100605P 2005-06-15 2005-06-15
PCT/US2006/023399 WO2006138511A2 (en) 2005-06-15 2006-06-15 Use of hif 1alfa modulators for treatment of cancer

Publications (1)

Publication Number Publication Date
ATE470439T1 true ATE470439T1 (de) 2010-06-15

Family

ID=37571192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784964T ATE470439T1 (de) 2005-06-15 2006-06-15 Verwendung von hif 1alfa modulatoren zur behandlung von krebs

Country Status (13)

Country Link
US (1) US8530404B2 (de)
EP (1) EP1919463B9 (de)
JP (2) JP5410751B2 (de)
KR (1) KR20080028918A (de)
CN (1) CN101242817B (de)
AT (1) ATE470439T1 (de)
AU (1) AU2006259352A1 (de)
BR (1) BRPI0611670A2 (de)
CA (1) CA2611785A1 (de)
DE (1) DE602006014843D1 (de)
IL (1) IL188101A (de)
MX (1) MX2007016160A (de)
WO (1) WO2006138511A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357175A1 (de) 2003-06-06 2011-08-17 Fibrogen, Inc. Isochinolin-Derivate UND DEREN VERWENDUNGEN ZUR ERHOEHUNG DES GEHALTES VON ENDOGENEM ERYTHROPOIETIN
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
EP2044028B1 (de) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisochinoline zur stabilisierung des hypoxie-induzierten faktors (hif)
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) * 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
EP2111399A2 (de) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenon-verbindungen mit prolylhydroxylase-hemmungsaktivität sowie zusammensetzungen daraus und anwendungen davon
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683956C (en) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008241577B2 (en) * 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
US8097620B2 (en) * 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
AU2008248234B2 (en) * 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
WO2008157177A1 (en) * 2007-06-13 2008-12-24 The Uab Research Foundation Methods for modulating osteoblast cell differentiation and bone generation through inhibition of a prolyl hydroxylase
EP2227475B1 (de) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridinderivate zur verwendung bei der behandlung von durch hif vermittelten leiden
US20110039879A1 (en) * 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) * 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (de) 2011-06-06 2018-03-17
MX2013014310A (es) * 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013082624A2 (en) * 2011-12-01 2013-06-06 The Ohio State University Materials and methods related to nsaid chemoprevention in colorectal cancer
NZ700760A (en) 2012-03-09 2016-08-26 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
KR102145272B1 (ko) 2012-07-16 2020-08-18 피브로겐, 인크. 이소퀴놀린 화합물의 제조 방법
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6491093B2 (ja) 2012-07-16 2019-03-27 フィブロジェン インコーポレイテッド プロリルヒドロキシラーゼ阻害剤の結晶形態
MX360048B (es) 2013-01-24 2018-10-19 Fibrogen Inc Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
EP3247355A4 (de) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Feste formen von 2-(5-(3-fluorphenyl)-3-hydroxypicolinamido)essigsäure, zusammensetzungen und verwendungen davon
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
WO2017110791A1 (ja) 2015-12-21 2017-06-29 株式会社東京精密 切断用ブレードの製造方法、及び切断用ブレード
CN107115355B (zh) * 2017-05-26 2020-01-17 昆明医科大学 一种含有无机砷化合物的药物组合物及其应用
WO2019138084A1 (en) * 2018-01-11 2019-07-18 Institut Pasteur Phenanthrolinone derivatives for use in the treatment of bacterial infections
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
JP7535285B2 (ja) * 2019-08-02 2024-08-16 公立大学法人大阪 腫瘍関連マクロファージ賦活化剤
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
GB202301059D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
US5916898A (en) 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
ATE255581T1 (de) 1997-10-24 2003-12-15 Fibrogen Inc Phenanthrolin-derivate
IL136454A0 (en) 1997-12-04 2001-06-14 Genzyme Corp Compositions and methods for inducing gene expression
US6124131A (en) 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
US6506936B1 (en) 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
US7396922B2 (en) 2001-11-28 2008-07-08 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
MXPA04006034A (es) 2001-12-19 2005-03-31 Johnson & Johnson Heterocompuestos tetraciclicos como moduladores de receptor de estroeno.
GB0211920D0 (en) * 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
MXPA05004722A (es) * 2002-11-01 2005-08-03 Univ Pennsylvania Composiciones y metodos para la inhibicion del factor inducible por hipoxia 1 alfa con acido ribonucleico corto de interferencia.
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
EP2357175A1 (de) * 2003-06-06 2011-08-17 Fibrogen, Inc. Isochinolin-Derivate UND DEREN VERWENDUNGEN ZUR ERHOEHUNG DES GEHALTES VON ENDOGENEM ERYTHROPOIETIN
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
WO2006010920A1 (en) * 2004-07-30 2006-02-02 Isis Innovation Limited Soluble polypeptide

Also Published As

Publication number Publication date
JP2008543864A (ja) 2008-12-04
HK1117422A1 (en) 2009-02-13
EP1919463B1 (de) 2010-06-09
DE602006014843D1 (de) 2010-07-22
JP2014012690A (ja) 2014-01-23
EP1919463A2 (de) 2008-05-14
US8530404B2 (en) 2013-09-10
CA2611785A1 (en) 2006-12-28
CN101242817A (zh) 2008-08-13
EP1919463B9 (de) 2011-02-02
MX2007016160A (es) 2008-03-07
IL188101A0 (en) 2008-04-13
JP5410751B2 (ja) 2014-02-05
CN101242817B (zh) 2016-08-31
AU2006259352A1 (en) 2006-12-28
WO2006138511A2 (en) 2006-12-28
BRPI0611670A2 (pt) 2016-11-16
WO2006138511A3 (en) 2007-03-29
KR20080028918A (ko) 2008-04-02
IL188101A (en) 2012-10-31
US20070004627A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
IL258880A (en) Diarylhydantoin compounds
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201100874A1 (ru) Соединения для лечения рака
EP4125846A4 (de) Pyrazolylpropanamidverbindungen und verwendungen davon zur behandlung von prostatakrebs
EP4259639A4 (de) Kombinationstherapien zur behandlung von krebs
EP4259638A4 (de) Kombinationstherapien zur behandlung von krebs
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
WO2009154790A3 (en) Novel metastasis suppressor genes and uses thereof
TW200716132A (en) Novel chemical compounds
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EP4313316A4 (de) Kombinationstherapien zur behandlung von krebs
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
TW200716579A (en) Novel chemical compounds
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties